Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
LIV-1 mAb - 01 | PCC | Solid Tumor | Colorectal cancer,Breast cancer |
Anti-LIV-1 mAb captured on CM5 chip via anti-human IgG Fc antibody can bind Human LIV-1, His Tag (Cat. No. LV1-H5223) with an affinity constant of 5.24 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ladiratuzumab vedotin | MK6440; MK-6440; SGN-LIV1A | Phase 2 Clinical | Seattle Genetics Inc, Merck Sharp & Dohme Corp | Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
BRY-812 | BRY-812 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.